What Is Tesamorelin? A Research Overview

Tesamorelin is a synthetic growth hormone–releasing hormone (GHRH) analog studied in clinical and preclinical research for its effects on the growth hormone (GH) / insulin-like growth factor 1 (IGF-1) axis. The tesamorelin offered here is a research-use-only (RUO) material intended solely for laboratory investigation. It is not the FDA-approved prescription medicine and is not for human use. While tesamorelin is approved by the FDA as a prescription drug (marketed as Egrifta) for a specific indication, that regulatory status applies to the licensed pharmaceutical product — not to research material.

Quick facts

• Class: GHRH (growth hormone–releasing hormone) analog
• Research focus: GH / IGF-1 axis research
• Structure: modified 44–amino acid human GHRH sequence with an N-terminal hexenoyl modification
• Form: lyophilized powder, ≥99% HPLC purity, third-party tested

What is Tesamorelin?

Tesamorelin is a stabilized analog of human growth hormone–releasing hormone. Structurally, it is a synthetically produced 44–amino acid sequence of human GHRH with a hexenoyl moiety attached to the tyrosine residue at the amino terminus. This modification is reported to confer resistance to degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), extending stability relative to native GHRH. As a GHRH analog, it is used in research as a tool to investigate how a GHRH-receptor agonist influences endogenous GH secretion and downstream IGF-1 signaling.

What does the research show?

Published clinical research describes outcomes observed in study participants, not in any reader of this article. In phase 3 randomized controlled trials in adults with HIV-associated lipodystrophy, investigators reported that tesamorelin reduced visceral adipose tissue compared with placebo over 26 weeks, alongside increases in serum IGF-1 [1][2]. A 2026 meta-analysis pooling randomized controlled trials reported associations with reductions in visceral adipose tissue, trunk fat, and hepatic fat percentage, along with improvements in IGF-1 levels [3]. These findings are attributed to the published trial populations and are presented strictly to summarize the scientific literature.

Mechanisms studied in the lab

• GHRH receptor agonism: studied as an agonist at the GHRH receptor on anterior pituitary cells.
• GH release: research describes stimulation of endogenous GH secretion in a pattern characterized as more physiological than direct GH administration.
• IGF-1 axis: increased GH secretion is associated in the literature with elevated downstream IGF-1, a key readout in GH/IGF-1 axis studies.
• Enzymatic stability: the N-terminal modification is studied for conferring resistance to DPP-4 degradation.

Research status and safety

The tesamorelin sold here is supplied exclusively as a research-use-only chemical for in vitro and laboratory investigation by qualified researchers. It is not a drug, supplement, or medical product, is not intended to diagnose, treat, cure, or prevent any disease, and is not for human or animal consumption. Although tesamorelin is the active ingredient in an FDA-approved prescription medicine for a specific clinical indication, that approval does not extend to research material.

Handling

Tesamorelin is supplied as a lyophilized (freeze-dried) powder. Researchers typically store the sealed vial cold and protected from light until use, then reconstitute prior to laboratory work. For general technique, see our guide on how to reconstitute a research peptide. To view this product and related items, browse the catalog or the product page: Tesamorelin — research-grade, ≥99% pure.

FAQ

Is tesamorelin a peptide or a hormone? Tesamorelin is a synthetic peptide analog of the hormone GHRH. In research it is classified as a GHRH-receptor agonist peptide.

Is this the same as the FDA-approved Egrifta? No. Tesamorelin is the active molecule in an FDA-approved prescription medicine, but the material offered here is a research-use-only chemical — not a pharmaceutical product and not for human use.

What axis does tesamorelin research focus on? Studies center on the GH / IGF-1 axis — how a DPP-4–resistant GHRH analog stimulates endogenous GH release and downstream IGF-1.

References

1. Bedimo R. Growth hormone and tesamorelin in HIV-associated lipodystrophy. HIV AIDS (Auckl). 2011.
2. Spooner LM, Olin JL. Tesamorelin: a GHRH analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012.
3. Badran AS, et al. Body composition and metabolic outcomes of tesamorelin: a meta-analysis of RCTs. Obes Res Clin Pract. 2026.

For research use only. Not for human or veterinary use. The research material is not the FDA-approved medicine. Statements have not been evaluated by the FDA.